Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

The Lancet Gastroenterology & Hepatology Commissioners, Graham S. Cooke, Isabelle Andrieux-Meyer, Tanya L. Applegate, Rifat Atun, Jessica R. Burry, Hugo Cheinquer, Geoff Dusheiko, Jordan J. Feld, Charles Gore, Max G. Griswold, Saeed Hamid, Margaret E. Hellard, Jin Lin Hou, Jess Howell, Jidong Jia, Natalia Kravchenko, Jeffrey V. Lazarus, Maud Lemoine, Olufunmilayo A. Lesi & 31 others Liudmyla Maistat, Brian J. McMahon, Homie Razavi, Teri R. Roberts, Bryony Simmons, Mark W. Sonderup, C. Wendy Spearman, Bridie E. Taylor, David L. Thomas, Imam Waked, John W. Ward, Stefan Z. Wiktor, Ayman Abdo, Rakesh Aggarwal, Alessio Aghemo, Bandar Al-Judaibi, Mamun Al Mahtab, Arshad Altaf, Zyaad Ameen, Tarik Asselah, Oidov Baatarkkhuu, Ella Barber, Eleanor Barnes, Pascale Boulet, Louise Burrows, Maia Butsashvili, Erica Chan, Chelsea Chow, Ben Cowie, Chris Cunningham, James Ward

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.

LanguageEnglish
Pages135-184
Number of pages50
JournalThe Lancet Gastroenterology and Hepatology
Volume4
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The Lancet Gastroenterology & Hepatology Commissioners. / Accelerating the elimination of viral hepatitis : a Lancet Gastroenterology & Hepatology Commission. In: The Lancet Gastroenterology and Hepatology. 2019 ; Vol. 4, No. 2. pp. 135-184.
@article{f39be9079ee04433b2ff3d519ed3614f,
title = "Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission",
abstract = "Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65{\%} and a 90{\%} reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75{\%} of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.",
author = "{The Lancet Gastroenterology & Hepatology Commissioners} and Cooke, {Graham S.} and Isabelle Andrieux-Meyer and Applegate, {Tanya L.} and Rifat Atun and Burry, {Jessica R.} and Hugo Cheinquer and Geoff Dusheiko and Feld, {Jordan J.} and Charles Gore and Griswold, {Max G.} and Saeed Hamid and Hellard, {Margaret E.} and Hou, {Jin Lin} and Jess Howell and Jidong Jia and Natalia Kravchenko and Lazarus, {Jeffrey V.} and Maud Lemoine and Lesi, {Olufunmilayo A.} and Liudmyla Maistat and McMahon, {Brian J.} and Homie Razavi and Roberts, {Teri R.} and Bryony Simmons and Sonderup, {Mark W.} and Spearman, {C. Wendy} and Taylor, {Bridie E.} and Thomas, {David L.} and Imam Waked and Ward, {John W.} and Wiktor, {Stefan Z.} and Ayman Abdo and Rakesh Aggarwal and Alessio Aghemo and Bandar Al-Judaibi and {Al Mahtab}, Mamun and Arshad Altaf and Zyaad Ameen and Tarik Asselah and Oidov Baatarkkhuu and Ella Barber and Eleanor Barnes and Pascale Boulet and Louise Burrows and Maia Butsashvili and Erica Chan and Chelsea Chow and Ben Cowie and Chris Cunningham and James Ward",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/S2468-1253(18)30270-X",
language = "English",
volume = "4",
pages = "135--184",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Ltd",
number = "2",

}

Accelerating the elimination of viral hepatitis : a Lancet Gastroenterology & Hepatology Commission. / The Lancet Gastroenterology & Hepatology Commissioners.

In: The Lancet Gastroenterology and Hepatology, Vol. 4, No. 2, 01.02.2019, p. 135-184.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Accelerating the elimination of viral hepatitis

T2 - The Lancet Gastroenterology and Hepatology

AU - The Lancet Gastroenterology & Hepatology Commissioners

AU - Cooke, Graham S.

AU - Andrieux-Meyer, Isabelle

AU - Applegate, Tanya L.

AU - Atun, Rifat

AU - Burry, Jessica R.

AU - Cheinquer, Hugo

AU - Dusheiko, Geoff

AU - Feld, Jordan J.

AU - Gore, Charles

AU - Griswold, Max G.

AU - Hamid, Saeed

AU - Hellard, Margaret E.

AU - Hou, Jin Lin

AU - Howell, Jess

AU - Jia, Jidong

AU - Kravchenko, Natalia

AU - Lazarus, Jeffrey V.

AU - Lemoine, Maud

AU - Lesi, Olufunmilayo A.

AU - Maistat, Liudmyla

AU - McMahon, Brian J.

AU - Razavi, Homie

AU - Roberts, Teri R.

AU - Simmons, Bryony

AU - Sonderup, Mark W.

AU - Spearman, C. Wendy

AU - Taylor, Bridie E.

AU - Thomas, David L.

AU - Waked, Imam

AU - Ward, John W.

AU - Wiktor, Stefan Z.

AU - Abdo, Ayman

AU - Aggarwal, Rakesh

AU - Aghemo, Alessio

AU - Al-Judaibi, Bandar

AU - Al Mahtab, Mamun

AU - Altaf, Arshad

AU - Ameen, Zyaad

AU - Asselah, Tarik

AU - Baatarkkhuu, Oidov

AU - Barber, Ella

AU - Barnes, Eleanor

AU - Boulet, Pascale

AU - Burrows, Louise

AU - Butsashvili, Maia

AU - Chan, Erica

AU - Chow, Chelsea

AU - Cowie, Ben

AU - Cunningham, Chris

AU - Ward, James

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.

AB - Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.

UR - http://www.scopus.com/inward/record.url?scp=85059556382&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(18)30270-X

DO - 10.1016/S2468-1253(18)30270-X

M3 - Review article

VL - 4

SP - 135

EP - 184

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 2

ER -